Beacon’s strategic guidance was pivotal in crystallising our value proposition, both elevating our communication with prospective partners and developing our fund-raising pitch. Their ability to rapidly grasp the underlying genomic science and its application in biomarker-driven drug development set them apart. With a nuanced understanding of both the technical intricacies and the broader market landscape, they helped us craft a narrative that seamlessly bridged scientific innovation and commercial relevance.

Their feedback on our pitch materials was both practical and incisive, ensuring our messaging reflected the unique value of genomic insights—particularly in enabling patient stratification and accelerating therapeutic precision. Beacon’s collaborative approach energised our team and gave us the confidence to engage new partners with a clear, differentiated strategy grounded in real translational impact.

Working with Beacon was a game-changer for our program. Their expertise and leadership through our end-of-Phase 2 data review brought clarity and focus to a complex dataset, helping us see both the risks and the opportunities.

The strategic planning for Phase 3 was exceptionally thorough—Beacon anticipated regulatory hurdles, mapped out a clear path forward, and ensured our trial design was robust and competitive. Their support in partner selection was invaluable; we ended up with a collaborator who truly fits our needs. The process was collaborative, insightful, and always patient focused to  deliver the best outcome for our company.

FOUNDER

With over two decades of experience in the pharmaceutical and healthcare industries, specialising in Precision Medicines, Jill brings deep expertise in biomarker discovery, clinical development, regulatory strategy, and commercialisation.

Jill is recognised as a strategic and visionary leader with a track record of managing complex projects, ensuring goals are not only met but exceeded.

PARTNER

In a career spanning drug and diagnostic development and academic research, Emma has held leadership roles driving companion diagnostic development and delivery of Precision Medicine strategies for complex Phase III clinical trials, specialising in IVDR.

With a pioneering mindset, she excels at tackling challenges, setting precedents, and developing innovative processes to optimise outcomes and efficiency.

SENIOR CONSULTANT

With expertise across multiple biopharma therapeutic areas and specialising in early phase clinical studies, James’ leadership, has led to the successful deployment of multiple Precision Medicine strategies, through to device approvals.

James is a renowned leader of complex Precision Medicine clinical trials, driven to deliver innovative solutions and meet the needs of stakeholders and patients.

SENIOR CONSULTANT

A leading oncology expert with 20+ years in Pharma / Biotech and academic research and a career spanning early and late-stage clinical development, Chris is a recognised expert in innovative clinical trial design.

Chris has served as Chief Development Officer for numerous novel oncology therapies entering first-in-human and proof-of-concept studies.

SENIOR CONSULTANT

A pioneer in the launch and commercialisation of Precision Medicines, Joe brings 30 years of pharma experience, working across the globe, to drive patient access to transformative medicines.

Under Joe’s leadership, key diagnostic challenges have been overcome, new clinical workflows established, and quality assured to ensure patient access to Precision Medicines.

At Beacon, we bring together a team of over 20 highly skilled associates with expertise spanning every stage of precision medicine development:

Technology Experts – Specialists in next-generation technologies.

Commercial Leaders – Experienced in market strategy, pricing, reimbursement, and launch planning.

Diagnostic Validation Experts – Professionals in assay development, analytical validation, and regulatory compliance.

Drug Development Strategists – Leaders in clinical trial design, regulatory submissions, and lifecycle management.